SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling

Nat Immunol. 2022 Nov;23(11):1588-1599. doi: 10.1038/s41590-022-01326-8. Epub 2022 Oct 20.

Abstract

Dysfunctional CD8+ T cells, which have defective production of antitumor effectors, represent a major mediator of immunosuppression in the tumor microenvironment. Here, we show that SUSD2 is a negative regulator of CD8+ T cell antitumor function. Susd2-/- effector CD8+ T cells showed enhanced production of antitumor molecules, which consequently blunted tumor growth in multiple syngeneic mouse tumor models. Through a quantitative mass spectrometry assay, we found that SUSD2 interacted with interleukin (IL)-2 receptor α through sushi domain-dependent protein interactions and that this interaction suppressed the binding of IL-2, an essential cytokine for the effector functions of CD8+ T cells, to IL-2 receptor α. SUSD2 was not expressed on regulatory CD4+ T cells and did not affect the inhibitory function of these cells. Adoptive transfer of Susd2-/- chimeric antigen receptor T cells induced a robust antitumor response in mice, highlighting the potential of SUSD2 as an immunotherapy target for cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes*
  • Cell Line, Tumor
  • Immunotherapy / methods
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms* / metabolism
  • Receptors, Interleukin-2 / metabolism
  • Signal Transduction
  • Tumor Microenvironment

Substances

  • Receptors, Interleukin-2
  • SVS-1 protein, mouse